Unit Dose Manufacturing Global Market Report 2024

The unit dose manufacturing market size has grown exponentially in recent years. It will grow from $27.36 billion in 2023 to $33.16 billion in 2024 at a compound annual growth rate (CAGR) of 21.2%. The expansion observed in the historical period can be attributed to traditional pharmaceutical manufacturing practices, regulatory advancements in drug packaging, an increased demand for personalized medicine, the growth of the aging population, and a rise in the prevalence of chronic diseases.

The unit dose manufacturing market size is expected to see exponential growth in the next few years. It will grow to $71.83 billion in 2028 at a compound annual growth rate (CAGR) of 21.3%. The anticipated growth in the forecast period can be attributed to the adoption of Industry 4.0 in pharmaceutical manufacturing, a heightened emphasis on personalized and precision medicine, regulatory focus on drug safety and efficacy, the expansion of pharmaceutical outsourcing, and a growing demand for patient-centric drug delivery. Prominent trends expected during the forecast period include the implementation of advanced automation in unit dose manufacturing, the integration of IoT in pharmaceutical packaging, the customization of unit dose packaging for specific drugs, the adoption of sustainable and eco-friendly packaging materials, and the growth of 3D printing in personalized drug manufacturing.

The anticipated increase in healthcare spending is set to drive the growth of the unit dose manufacturing market in the coming years. Healthcare spending encompasses all costs related to delivering health services, family planning initiatives, nutrition programs, and emergency assistance with a focus on health. The escalation in healthcare expenditure is expected to foster the advancement and development of various health-related services, including unit dose manufacturing. As an illustration, in February 2023, the Centers for Medicare & Medicaid Services reported a 2.7% increase in healthcare spending in the United States, reaching $12,914 per person in 2021, totaling $4.3 trillion. Additionally, healthcare spending constituted 18.3% of the country's GDP. Consequently, the upward trend in healthcare spending is a driving force behind the growth of the unit dose manufacturing market.

The burgeoning demand for personalized medicine is poised to be a key driver of growth in the unit dose manufacturing market. Personalized medicine involves the use of knowledge about an individual's genes or proteins to prevent, detect, or treat diseases. Unit dose manufacturing plays a pivotal role in personalized medicine by providing a platform for producing individualized doses tailored to the specific needs of patients. As highlighted by the Personalized Medicine Coalition, approximately 34% of all newly approved therapeutic molecular entities in 2022 were personalized medicines, with 12 such medicines receiving approval from the US Food and Drug Administration (FDA). This surge in demand for personalized medicine is a significant factor propelling the expansion of the unit dose manufacturing market.

A notable trend gaining traction is product innovation. Major companies within the market are actively engaged in developing innovative products to maintain and strengthen their market position. For instance, in March 2021, Ritedose Corporation, a US-based contract pharmaceutical manufacturer, introduced a new unit-dose syringe product, Succinylcholine Chloride Injection 200 mg/10 mL (20 mg/mL). This prefilled syringe product is labeled with warnings, color-coded to ASTM drug class standards, and prepared for administration in acute care settings, eliminating the need for in-hospital compounding. The predetermined concentration of the prefilled syringe addresses concerns related to dosage accuracy in patient care.

Strategic partnerships are emerging as a prominent strategy adopted by major players to sustain and enhance their position in the unit dose manufacturing market. Strategic partnerships involve leveraging each other's strengths and resources to achieve mutual benefits and success. In November 2023, iA, a US-based provider of integrated pharmacy fulfillment platforms, announced a distributor agreement with Euclid Medical Products, a US-based specialist in multi-unit automated packaging and barcoding systems. This collaboration involves integrating Euclid’s Axial Adherence Packaging Technology into iA's NEXiA Enterprise Software Suite, expanding the capabilities of centralized fulfillment solutions. This partnership offers multiple medication dispensing methods, including multi- and unit-dose automated packaging, providing comprehensive solutions to meet diverse healthcare needs.

In August 2022, LTS Lohmann Therapie-Systeme AG, a Germany-based pharmaceutical technology company specializing in drug delivery systems, acquired Tapemark Inc. for an undisclosed amount. This acquisition positions LTS Lohmann Therapie-Systeme AG as a leading contract development and manufacturing organization for transdermal patches and oral thin films while expanding its footprint in the US. Tapemark Inc., based in the US, is a full-service contract development and manufacturing organization specializing in transdermal, oral thin film, and unit-dose products. The acquisition reflects a commitment to growth and diversification within the unit dose manufacturing sector.

Major companies operating in the unit dose manufacturing market report are Nipro Corporation, Thermo Fisher Scientific Inc., Amcor PLC, Berry Global, CCL Industries, Sealed Air Corporation, Huhtamäki Oyj, Catalent Inc., AptarGroup, Schott AG, West Pharmaceuticals Services Inc., Constantia Flexibles Group GmbH, Gerresheimer AG, RPC Group, Klöckner Pentaplast Group, Stevanato Group, Bemis Company, Corden Pharma GmbH, LTS Lohmann Therapie-Systeme AG, PCI Pharma Services, Comar LLC, Renaissance Lakewood LLC, Mikart LLC, Tapemark Company Inc., Bilcare Research, Medical Packaging Inc., American Health Packaging, Aphena Pharma Solutions.

North America was the largest region in the unit dose manufacturing market in 2023. The regions covered in the unit dose manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the unit dose manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary products of unit dose manufacturing include liquid unit dose, solid unit dose, and others. A liquid unit dose specifically denotes a predetermined and customized amount of liquid medication or chemical enclosed in a single packaging unit, typically designed for single-use delivery. The sourcing methods for unit dose manufacturing include both in-house production and outsourcing, with utilization by various entities such as independent pharmacies, long-term care facilities, hospitals, and others.

The unit dose manufacturing research report is one of a series of new reports that provides unit dose manufacturing market statistics, including the unit dose manufacturing industry's global market size, regional shares, competitors with unit dose manufacturing market share, detailed unit dose manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the unit dose manufacturing industry. This unit dose manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The unit dose manufacturing market consists of sales of sachets, small bottles, tubes, and pods. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.